Back to Search Start Over

Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls.

Authors :
Bellenguez C
Charbonnier C
Grenier-Boley B
Quenez O
Le Guennec K
Nicolas G
Chauhan G
Wallon D
Rousseau S
Richard AC
Boland A
Bourque G
Munter HM
Olaso R
Meyer V
Rollin-Sillaire A
Pasquier F
Letenneur L
Redon R
Dartigues JF
Tzourio C
Frebourg T
Lathrop M
Deleuze JF
Hannequin D
Genin E
Amouyel P
Debette S
Lambert JC
Campion D
Source :
Neurobiology of aging [Neurobiol Aging] 2017 Nov; Vol. 59, pp. 220.e1-220.e9. Date of Electronic Publication: 2017 Jul 14.
Publication Year :
2017

Abstract

We performed whole-exome and whole-genome sequencing in 927 late-onset Alzheimer disease (LOAD) cases, 852 early-onset AD (EOAD) cases, and 1273 controls from France. We assessed the evidence for gene-based association of rare variants with AD in 6 genes for which an association with such variants was previously claimed. When aggregating protein-truncating and missense-predicted damaging variants, we found exome-wide significant association between EOAD risk and rare variants in SORL1, TREM2, and ABCA7. No exome-wide significant signal was obtained in the LOAD sample, and significance of the order of 10 <superscript>-6</superscript> was observed in the whole AD group for TREM2. Our study confirms previous gene-level results for TREM2, SORL1, and ABCA7 and provides a clearer insight into the classes of rare variants involved. Despite different effect sizes and varying cumulative minor allele frequencies, the rare protein-truncating and missense-predicted damaging variants in TREM2, SORL1, and ABCA7 contribute similarly to the heritability of EOAD and explain between 1.1% and 1.5% of EOAD heritability each, compared with 9.12% for APOE ε4.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1558-1497
Volume :
59
Database :
MEDLINE
Journal :
Neurobiology of aging
Publication Type :
Academic Journal
Accession number :
28789839
Full Text :
https://doi.org/10.1016/j.neurobiolaging.2017.07.001